Literature DB >> 20363376

Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.

Lilia González-Cerón1, Alejandro Alvarado-Delgado, Jesus Martínez-Barnetche, Mario H Rodríguez, Marbella Ovilla-Muñoz, Fabián Pérez, Juan E Hernandez-Avila, Marco A Sandoval, Maria Del Carmen Rodríguez, Cuauhtémoc Villarreal-Treviño.   

Abstract

The polymorphism of Pvs25 and Pvs28 ookinete surface proteins, their association to circumsporozoite protein repeat (CSPr) genotypes (Vk210 and Vk247) and their infectivity to local Anopheles albimanus and Anopheles pseudopunctipennis were investigated in Plasmodium vivax-infected blood samples obtained from patients in Southern Mexico. The pvs25 and pvs28 complete genes were amplified, cloned and sequenced; and the CSPr genotype was determined by PCR amplification and hybridization. The amino acid Pvs25 and Pvs28 polymorphisms were mapped to their corresponding protein structure. Infected blood samples were simultaneously provided through artificial feeders to both mosquito species; the ratio of infected mosquitoes and oocyst numbers were recorded. The polymorphism of pvs25 and pvs28 was limited to few nucleotide positions, and produced three haplotypes: type A/A parasites presented Pvs25 and Pvs28 amino acid sequences identical to that of Sal I reference strain; parasites type B1 presented a mutation 130 Ile-->Thr in Pvs25, while type B2 presented 87 Gln-->Lys/130 Ile-->Thr in the same molecule. Both types B1 and B2 parasites presented changes in Pvs28 at 87 Asn-->Asp, 110 Tyr-->Asn and five GSGGE/D repeat sequences between the fourth EGF-like domain and the GPI. Most P. vivaxparasites from the coastal plains and the overlapping region were Pvs25/28 A/A, CSPrVk210 and were infective only to An. albimanus (p< or =0.0001). Parasites originating in foothills were Pvs25/28 type B1/B or B2/B and CSPrVk210 or Vk247, and were more infective to An. pseudopunctipennis than to An. albimanus (p< or =0.001). These results and the analysis of Pvs25/28 from other parts of the world indicated that non-synonymous variations in these proteins occur in amino acid residues exposed on the surface of the proteins, and are likely to interact with midgut mosquito ligands. We hypothesize that these molecules have been shaped by co-evolutionary adaptations of parasites to their susceptible vectors. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363376     DOI: 10.1016/j.meegid.2010.03.014

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  11 in total

1.  Antigenic repertoire of Plasmodium vivax transmission-blocking vaccine candidates from the Indian subcontinent.

Authors:  Surendra K Prajapati; Hema Joshi; Virendra K Dua
Journal:  Malar J       Date:  2011-05-02       Impact factor: 2.979

2.  Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan Province, China.

Authors:  Hui Feng; Li Zheng; Xiaotong Zhu; Gege Wang; Yanyan Pan; Ying Li; Yimei Yang; Yahui Lin; Liwang Cui; Yaming Cao
Journal:  Parasit Vectors       Date:  2011-11-28       Impact factor: 3.876

3.  Diversity and evolutionary genetics of the three major Plasmodium vivax merozoite genes participating in reticulocyte invasion in southern Mexico.

Authors:  Lilia González-Cerón; Rene Cerritos; Jordán Corzo-Mancilla; Frida Santillán
Journal:  Parasit Vectors       Date:  2015-12-21       Impact factor: 3.876

4.  Molecular epidemiology of Plasmodium vivax in Latin America: polymorphism and evolutionary relationships of the circumsporozoite gene.

Authors:  Lilia González-Cerón; Jesus Martinez-Barnetche; Ciro Montero-Solís; Frida Santillán; Aida M Soto; Mario H Rodríguez; Benjamin J Espinosa; Octavio A Chávez
Journal:  Malar J       Date:  2013-07-15       Impact factor: 2.979

5.  Genetic Spatiotemporal Anatomy of Plasmodium vivax Malaria Episodes in Greece, 2009-2013.

Authors:  Gregory Spanakos; Georges Snounou; Danai Pervanidou; Michael Alifrangis; Anna Rosanas-Urgell; Agoritsa Baka; Maria Tseroni; Annita Vakali; Evdokia Vassalou; Eleni Patsoula; Herve Zeller; Wim Van Bortel; Christos Hadjichristodoulou
Journal:  Emerg Infect Dis       Date:  2018-03       Impact factor: 6.883

6.  Temporal genetic changes in Plasmodium vivax apical membrane antigen 1 over 19 years of transmission in southern Mexico.

Authors:  Alejandro Flores-Alanis; Lilia González-Cerón; Frida Santillán; Cecilia Ximenez; Marco A Sandoval; René Cerritos
Journal:  Parasit Vectors       Date:  2017-05-02       Impact factor: 3.876

7.  Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates.

Authors:  Jung-Mi Kang; Hye-Lim Ju; Sung-Ung Moon; Pyo-Yun Cho; Young-Yil Bahk; Woon-Mok Sohn; Yun-Kyu Park; Seok Ho Cha; Tong-Soo Kim; Byoung-Kuk Na
Journal:  Malar J       Date:  2013-04-30       Impact factor: 2.979

8.  Genetic structure of Plasmodium vivax using the merozoite surface protein 1 icb5-6 fragment reveals new hybrid haplotypes in southern Mexico.

Authors:  René Cerritos; Lilia González-Cerón; José A Nettel; Ana Wegier
Journal:  Malar J       Date:  2014-01-29       Impact factor: 2.979

9.  Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.

Authors:  Ricardo A Chaurio; M Andreína Pacheco; Omar E Cornejo; Ester Durrego; Craig E Stanley; Andreína I Castillo; Sócrates Herrera; Ananias A Escalante
Journal:  PLoS Negl Trop Dis       Date:  2016-06-27

10.  Ookinete-Specific Genes and 18S SSU rRNA Evidenced in Plasmodium vivax Selection and Adaptation by Sympatric Vectors.

Authors:  Lilia González-Cerón; Mario H Rodríguez; Marbella T Ovilla-Muñoz; Frida Santillán-Valenzuela; Juan E Hernández-Ávila; María Carmen Rodríguez; Jesús Martínez-Barnetche; Cuauhtémoc Villarreal-Treviño
Journal:  Front Genet       Date:  2020-02-21       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.